The Emerging Importance of Transporter Proteins in the Psychopharmacological Treatment of the Pregnant Patient

REFERENCES

• Adkison K. D., Artru A. A., Powers K. M., Shen D. D. Contribution of probenecid-sensitive anion transport processes at the brain capillary endothelium and choroid plexus to the efficient efflux of valproic acid from the central nervous system. J. Pharmacol. Exp. Ther. 1994; 268: 797–805
   PubMed Web of Science ®Google Scholar
• Altshuler L. L., Cohen L., Szuba M. P., Burt V. K., Gitlin M., Mintz J. Pharmacologic management of psychiatric illness during pregnancy: dilemmas and guidelines. Am. J. Psych. 1996; 153: 592–606
   PubMed Web of Science ®Google Scholar
• Anglicheau D., Thervet E., Etienne I., de Ligny B. H., Le Meur Y., Touchard G., Buchler M., Laurent-Puig P., Tregouet D., Beaune P., Daly A., Legendre C., Marquet P. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin. Pharmacol. Ther. 2004; 75: 422–433
   PubMed Web of Science ®Google Scholar
• Aquilante C. L., Letrent S. P., Pollack G. M., Brouwer K. L. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 2000; 66: PL47–51
   PubMed Web of Science ®Google Scholar
• Atkinson D. E., Greenwood S. L., Sibley C. P., Glazier J. D., Fairbairn L. J. Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am. J. Physiol. Cell Physiol. 2003; 285: C584–591
   PubMed Web of Science ®Google Scholar
• Baldessarini R. J., Viguera A. C. Neuroleptic withdrawal in schizophrenic patients. Arch Gen. Psych. 1995; 52: 189–192
   PubMed Web of Science ®Google Scholar
• Balkovetz D. F., Tiruppathi C., Leibach F. H., Mahesh V. B., Ganapathy V. Evidence for an imipramine-sensitive serotonin transporter in human placental brush-border membranes. J. Biol. Chem. 1989; 264: 2195–2198
   PubMed Web of Science ®Google Scholar
• Baltes S., Gastens A. M., Fedrowitz M., Potschka H., Kaever V., Loscher W. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein. Neuropharmacology 2007; 52: 333–346
   PubMed Web of Science ®Google Scholar
• Bottalico B., Larsson I., Brodszki J., Hernandez-Andrade E., Casslen B., Marsal K., Hansson S. R. Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies. Placenta 2004; 25: 518–529
   PubMed Web of Science ®Google Scholar
• Boulton D. W, DeVane C. L, Liston H. L., Markowitz J. S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci. 2002; 71: 163–169
   PubMed Web of Science ®Google Scholar
• Bourget P., Roulot C., Fernandez H. Models for placental transfer studies of drugs. Clin. Pharmacokinet. 1995; 28: 161–180
   PubMed Web of Science ®Google Scholar
• Brown D., Goosen T. C., Chetty M., Hamman J. H. Effect of oral contraceptives on the transport of chlorpromazine across the CACO-2 intestinal epithelial cell line. Eur. J. Pharm. Biopharm. 2003; 56: 159–165
   PubMed Web of Science ®Google Scholar
• Briz O., Serrano M. A., MacIas R. I., Gonzalez-Gallego J., Marin J. J. Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem. J. 2003; 371(Pt 3)897–905
   PubMed Web of Science ®Google Scholar
• Burke K. C., Burke J. D., Jr., Rae D. S., Regier D. A. Comparing age at onset of major depression and other psychiatric disorders by birth cohorts in five US community populations. Arch. Gen. Psych. 1991; 48: 789–795
   PubMed Web of Science ®Google Scholar
• Casiano M. E., Hawkins D. R. Major mental illness and childbearing: a role for the consultation-liaison psychiatrist in obstetrics. Psychiatr. Clin. North Amer. 1987; 10: 37–51
   Web of Science ®Google Scholar
• Ceckova M., Libra A., Pavek P., et al. Expression and functional activity of breast cancer resistance protein transporter in human choriocarcinoma cell line BeWo. Clin. Exp. Pharmacol. Physiol. 2006; 33: 58–65
   PubMed Web of Science ®Google Scholar
• Chowbay B., Cumaraswamy S., Cheung Y. B., Zhou Q., Lee E. J. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003; 13: 89–95
   PubMedGoogle Scholar
• Cohen L. S., Altshuler L. L., Harlow B. L., et al. Relapse of major depression during pregnancy in womenwho maintain or discontinue antidepressant treatment. JAMA 2006; 295: 499–507
   PubMed Web of Science ®Google Scholar
• Cooray H. C., Blackmore C. G., Maskell L., Barrand M. A. Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport 2002; 13: 2059–2063
   PubMed Web of Science ®Google Scholar
• Cordon-Cardo C., O'Brien J. P., Casals D., Rittman-Grauer L., Biedler J. L., Melamed M. R., Bertino J. R. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. 1989; 86: 695–698
   PubMed Web of Science ®Google Scholar
• Dean M., Rzhetsky A., Allikmets R. The human ATP-binding cassette (ABC) transporter superfamily. Genome Res. 2001; 11: 1156–1166
   PubMed Web of Science ®Google Scholar
• DeVane C. L., Stowe Z. N., Donovan J. L, Newport D. J., et al. Therapeutic drug monitoring of psychoactive drugs during pregnancy in the genomic era: Challenges and opportunities. J Psychopharmacol. 2006; 20(Suppl 4)54–59
   PubMedGoogle Scholar
• Doran A., Obach R. S., Smith B. J., et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. 2005; 33: 165–174
   PubMed Web of Science ®Google Scholar
• Doyle L. A., Yang W., Abruzzo L. V., Krogmann T., Gao Y., Rishi A. K., Ross D. D. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA 1998; 95: 15665–15670
   PubMed Web of Science ®Google Scholar
• Drescher S., Schaeffeler E., Hitzl M., Hofmann U., Schwab M., Brinkmann U., Eichelbaum M., Fromm M. F. MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Br. J. Clin. Pharmacol. 2002; 53: 526–534
   PubMed Web of Science ®Google Scholar
• Evseenko D. A., Paxton J. W., Keelan J. A. Transport across the placenta: impact on drug efficacy and toxicity. Expert Opin. Drug Metab. Toxicol. 2006; 2: 51–69
   PubMed Web of Science ®Google Scholar
• Evseenko D. A., Paxton J. W., Keelan J. A. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab. Disp. 2007; 35: 595–601
   PubMed Web of Science ®Google Scholar
• Flens M. J., Zaman G. J., van der Valk P., Izquierdo M. A., Schroeijers A. B., Scheffer G. L., van der Groep P., de Haas M., Meijer C. J., Scheper R. J. Tissue distribution of the multidrug resistance protein. Am. J. Pathol. 1996; 148: 1237–1247
   PubMed Web of Science ®Google Scholar
• Gentile S. Clinical utilization of atypical antipsychotics in pregnancy and lactation. Ann. Pharmacother. 2004; 38: 1265–1271
   PubMed Web of Science ®Google Scholar
• Giroux M., Teixera M. G., Dumas J. C., Desprats R., Grandjean H., Houin G. Influence of maternal blood flow on the placental transfer of three opioids--fentanyl, alfentanil, sufentanil. Biol Neonate 1997; 72: 133–141
   PubMedGoogle Scholar
• Gerloff T., Schaefer M., Johne A., Oselin K., Meisel C., Cascorbi I., Roots I. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br. J. Clin. Pharmacol. 2002; 54: 610–616
   PubMed Web of Science ®Google Scholar
• Goto M., Masuda S., Saito H., Uemoto S., Kiuchi T., Tanaka K., Inui K. C3435T polymorphism in the MDR1 gene affects the enterocyte expression level of CYP3A4 rather than Pgp in recipients of living-donor liver transplantation. Pharmacogenetics 2002; 12: 451–457
   PubMedGoogle Scholar
• Hitzl M., Schaeffeler E., Hocher B., Slowinski T., Halle H., Eichelbaum M., Kaufmann P., Fritz P., Fromm M. F., Schwab M. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 2004; 14: 309–318
   PubMedGoogle Scholar
• Hoffmeyer S., Burk O., von Richter O., Arnold H. P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. USA 2000; 97: 3473–3478
   PubMed Web of Science ®Google Scholar
• Horinouchi M., Sakaeda T., Nakamura T., Morita Y., Tamura T., Aoyama N., Kasuga M., Okumura K. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm. Res. 2002; 19: 1581–1585
   PubMed Web of Science ®Google Scholar
• Haufroid V., Mourad M., Van Kerckhove V., Wawrzyniak J., De Meyer M., Eddour D. C., Malaise J., Lison D., Squifflet J. P., Wallemacq P. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics 2004; 14: 147–454
   PubMedGoogle Scholar
• Hendrick V., Stowe Z. N., Altshuler L. L., Hwang S., Lee E., Haynes D. Placental passage of antidepressant medications. Am. J. Psych. 2003; 160: 993–996
   PubMed Web of Science ®Google Scholar
• Hesselink D. A., van Schaik R. H., van der Heiden I. P., van der Werf M., Gregoor P. J., Lindemans J., Weimar W., van Gelder T. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin. Pharmacol. Ther. 2003; 74: 245–254
   PubMed Web of Science ®Google Scholar
• Hitzl M., Schaeffeler E., Hocher B., Slowinski T., Halle H., Eichelbaum M., Kaufmann P., Fritz P., Fromm M. F., Schwab M. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 2004; 14: 309–318
   PubMedGoogle Scholar
• Honjo Y., Morisaki K., Huff L. M., Robey R. W., Hung J., Dean M., Bates S. E. Single-nucleotide polymorphism (SNP) analysis in the ABC half-transporter ABCG2 (MXR/BCRP/ABCP1). Cancer Biol. Ther. 2002; 1: 696–702
   PubMed Web of Science ®Google Scholar
• Lida A., Saito S., Sekine A., Mishima C., Kitamura Y., Kondo K., Harigae S., Osawa S., Nakamura Y. Catalog of 605 single-nucleotide polymorphisms (SNPs) among 13 genes encoding human ATP-binding cassette transporters: ABCA4, ABCA7, ABCA8, ABCD1, ABCD3, ABCD4, ABCE1, ABCF1, ABCG1, ABCG2, ABCG4, ABCG5, and ABCG8. J. Hum. Genet. 2002; 47: 285–310
   PubMed Web of Science ®Google Scholar
• Imai Y., Nakane M., Kage K., Tsukahara S., Ishikawa E., Tsuruo T., Miki Y., Sugimoto Y. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. 2002; 1: 611–616
   PubMed Web of Science ®Google Scholar
• Ito S., Ieiri I., Tanabe M., Suzuki A., Higuchi S., Otsubo K. Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 2001; 11: 175–184
   PubMedGoogle Scholar
• Jin R. F., Sun R. P., Xu X. P. Expression of multidrug resistance gene and topiramate affect expression of multidrug resistance gene in the hippocampus of spontaneous epileptic rats. Zhonghua Er Ke Za Zhi. 2005; 43: 733–737
   PubMedGoogle Scholar
• Johne A., Kopke K., Gerloff T., Mai I., Rietbrock S., Meisel C., Hoffmeyer S., Kerb R., Fromm M. F., Brinkmann U., Eichelbaum M., Brockmoller J., Cascorbi I., Roots I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin. Pharmacol. Ther. 2002; 72: 584–594
   PubMed Web of Science ®Google Scholar
• Jonker J. W., Smit J. W., Brinkhuis R. F., Maliepaard M., Beijnen J. H., Schellens J. H., Schinkel A. H. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. 2000; 92: 1651–1656
   PubMed Web of Science ®Google Scholar
• Jonker J. W., Buitelaar M., Wagenaar E., Van Der Valk M. A., Scheffer G. L., Scheper R. J., Plosch T., Kuipers F., Elferink R. P., Rosing H., Beijnen J. H., Schinkel A. H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci USA 2002; 99: 15649–15654
   PubMed Web of Science ®Google Scholar
• Juliano R. L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta 1976; 455: 152–162
   PubMed Web of Science ®Google Scholar
• Katoh M., Nakajima M., Yamazaki H., Yokoi T. Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur. J. Pharm. Sci. 2001; 12: 505–513
   PubMed Web of Science ®Google Scholar
• Kim R. B., Fromm M. F., Wandel C., Leake B., Wood A. J., Roden D. M., Wilkinson G. R. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J. Clin. Invest. 1998; 101: 289–294
   PubMed Web of Science ®Google Scholar
• Kim R. B., Wandel C., Leake B., Cvetkovic M., Fromm M. F., Dempsey P. J., Roden M. M., Belas F., Chaudhary A. K., Roden D. M., Wood A. J., Wilkinson G. R. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharm. Res. 1999; 16: 408–414
   PubMed Web of Science ®Google Scholar
• Kim R. B., Leake B. F., Choo E. F., Dresser G. K., Kubba S. V., Schwarz U. I., Taylor A., Xie H. G., McKinsey J., Zhou S., Lan L. B., Schuetz J. D., Schuetz E. G., Wilkinson G. R. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin. Pharmacol. Ther. 2001; 70: 189–199
   PubMed Web of Science ®Google Scholar
• Kobayashi D., Ieiri I., Hirota T., Takane H., Maegawa S., Kigawa J., Suzuki H., Nanba E., Oshimura M., Terakawa N., Otsubo K., Mine K., Sugiyama Y. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Disp. 2005; 33: 94–101
   PubMed Web of Science ®Google Scholar
• Kumar S., Wong H., Yeung S. A., Riggs K. W., Abbott F. S., Rurak D. W. Disposition of valproic acid in maternal, fetal, and newborn sheep. I: placental transfer, plasma protein binding, and clearance. Drug Metab. Dispos. 2000; 28: 845–856
   PubMed Web of Science ®Google Scholar
• Kunta J. R., Sinko P. J. Intestinal drug transporters: in vivo function and clinical importance. Curr. Drug Metab. 2004; 5: 109–124
   PubMed Web of Science ®Google Scholar
• Kurata Y., Ieiri I., Kimura M., Morita T., Irie S., Urae A., Ohdo S., Ohtani H., Sawada Y., Higuchi S., Otsubo K. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin. Pharmacol. Ther. 2002; 72: 209–219
   PubMed Web of Science ®Google Scholar
• Kuzuya T., Kobayashi T., Moriyama N., Nagasaka T., Yokoyama I., Uchida K., Nakao A., Nabeshima T. Amlodipine, but not MDR1 polymorphisms, alters the pharmacokinetics of cyclosporine A in Japanese kidney transplant recipients. Transplantation 2003; 76: 865–868
   PubMed Web of Science ®Google Scholar
• Lang T., Hitzl M., Burk O., Mornhinweg E., Keil A., Kerb R., Klein K., Zanger U. M., Eichelbaum M., Fromm M. F. Genetic polymorphisms in the multidrug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetics 2004; 14: 155–164
   PubMedGoogle Scholar
• Lankas G. R., Wise L. D., Cartwright M. E., Pippert T., Umbenhauer D. R. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. 1998; 12: 457–463
   PubMed Web of Science ®Google Scholar
• Larsen F., Priskorn M., Overo K. F. Lack of citalopram effect on oral digoxin pharmacokinetics. J. Clin. Pharmacol. 2001; 41: 340–346
   PubMed Web of Science ®Google Scholar
• Leach L., Clark P., Lampugnani M. G., Arroyo A. G., Dejana E., Firth J. A. Immunoelectron characterisation of the inter-endothelial junctions of human term placenta. J. Cell Sci. 1993; 104(Pt 4)1073–1081
   PubMed Web of Science ®Google Scholar
• Lee M. S., Lee H. Y., Lee H. J., Ryu S. H. Serotonin transporter promoter gene polymorphism and long-term outcome of antidepressant treatment. Psychiatr. Genet. 2004; 14: 111–115
   PubMed Web of Science ®Google Scholar
• Lin J. H., Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin. Pharmacokinet. 2003; 42: 59–98
   PubMed Web of Science ®Google Scholar
• Loscher W., Potschka H. Role of multidrug transporters in pharmacoresistance to antiepileptic drugs. J. Pharm. Exp. Ther. 2002; 301: 7–14
   PubMed Web of Science ®Google Scholar
• MacFarland A., Abramovich D. R., Ewen S. W., Pearson C. K. Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem. J. 1994; 26: 417–423
   PubMedGoogle Scholar
• Mahar Doan K. M., Humphreys J. E., Webster L. O., Wring S. A., Shampine L. J., Serabjit-Singh C. J., Adkison K. K., Polli J. W. Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J. Pharmacol. Exp. Ther. 2002; 303: 1029–1037
   PubMed Web of Science ®Google Scholar
• Maliepaard M., Scheffer G. L., Faneyte I. F., van Gastelen M. A., Pijnenborg A. C., Schinkel A. H., van De Vijver M. J., Scheper R. J., Schellens J. H. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 2001; 61: 3458–3464
   PubMed Web of Science ®Google Scholar
• Markowitz J. S., DeVane C. L., Malcolm R. L., Gefroh H. A., Wang J. S., Zhu H. J., Donovan J. L. Pharmacokinetics of olanzapine after single dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers. J. Clin. Pharmacol. 2006; 46: 164–171
   PubMed Web of Science ®Google Scholar
• Marzolini C., Paus E., Buclin T., Kim R. B. Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance. Clin. Pharmacol. Ther. 2004; 75: 13–33
   PubMed Web of Science ®Google Scholar
• McKenna K., Einarson A., Levinson A., Gideon K. Significant changes in antipsychotic drug use during pregnancy. Vet. Hum. Toxicol. 2004; 46: 44–46
   PubMedGoogle Scholar
• Meibohm B. The effect of CYP3A5 and MDR1 polymorphic expression on cyclosporine oral disposition in renal transplant patients. J. Clin. Pharmacol. 2003; 43: 555–564
   PubMed Web of Science ®Google Scholar
• Melchior J. C., Svensmark O., Trolle D. Placental transfer of phenobarbitone in epileptic women, and elimination in newborns. Lancet 1967; 2: 860–861
   PubMed Web of Science ®Google Scholar
• Meyer J. H., Wilson A. A., Sagrati S., Hussey D., Carella A., Potter W. Z., Ginovart N., Spencer E. P., Cheok A., Houle S. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am. J. Psych. 2004; 161: 826–835
   PubMed Web of Science ®Google Scholar
• Miyake K., Mickley L., Litman T., Zhan Z., Robey R., Cristensen B., Brangi M., Greenberger L., Dean M., Fojo T., Bates S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res. 1999; 59: 8–13
   PubMed Web of Science ®Google Scholar
• Molsa M., Heikkinen T., Hakkola J., Hakala K., Wallerman O., Wadelius M., Wadelius C., Laine K. Functional role of P-glycoprotein in the human blood-placental barrier. Clin. Pharmacol. Ther. 2005; 78: 123–131
   PubMed Web of Science ®Google Scholar
• Moriya Y., Nakamura T., Horinouchi M., Sakaeda T., Tamura T., Aoyama N., Shirakawa T., Gotoh A., Fujimoto S., Matsuo M., Kasuga M., Okumura K. Effects of polymorphisms of MDR1, MRP1, and MRP2 genes on their mRNA expression levels in duodenal enterocytes of healthy Japanese subjects. Biol. Pharm. Bull. 2002; 25: 1356–1359
   PubMed Web of Science ®Google Scholar
• Myllynen P. K., Pienimaki P. K., Vahakangas K. H. Transplacental passage of lamotrigine in a human placental perfusion system in vitro and in maternal and cord blood in vivo. Eur. J. Clin. Pharmacol. 2003; 58: 677–682
   PubMed Web of Science ®Google Scholar
• Mylona P., Hoyland J. A., Sibley C. P. Sites of mRNA expression of the cystic fibrosis (CF) and multidrug resistance (MDR1) genes in the human placenta of early pregnancy: No evidence for complementary expression. Placenta. 1999; 20: 493–496
   PubMed Web of Science ®Google Scholar
• Nakamura Y., Ikeda S., Furukawa T., Sumizawa T., Tani A., Akiyama S., Nagata Y. Function of P-glycoprotein expressed in placenta and mole. Biochem. Biophys. Res. Commun. 1997; 235: 849–853
   PubMed Web of Science ®Google Scholar
• Nakamura T., Sakaeda T., Horinouchi M., Tamura T., Aoyama N., Shirakawa T., Matsuo M., Kasuga M., Okumura K. Effect of the mutation (C3435T) at exon 26 of the MDR1 gene on expression level of MDR1 messenger ribonucleic acid in duodenal enterocytes of healthy Japanese subjects. Clin. Pharmacol. Ther. 2002; 71: 297–303
   PubMed Web of Science ®Google Scholar
• Newport D. S. J., Wilcox M. M., Stowe Z. N. Antidepressants during pregnancy and lactation: defining exposure and treatment issues. Sem. Perinatology 2001; 25: 177–190
   PubMed Web of Science ®Google Scholar
• Newport J., Calamaras M. R., DeVane C. L., Donovan J. L., Beach A. J., Winn S., Knight B. T., Gibson B. B., Viguera A. C., Owens M. J., Nemeroff C. B., Stowe Z. N. Atypical antipsychotic administration during late pregnancy: Placental passage and obstetrical outcomes. Am. J. Psychiatry 2007, in press.
   Web of Science ®Google Scholar
• Ochs H. R., Greenblatt D. J., Verburg-Ochs B., Labedski L. Chronic treatment with fluvoxamine, clovoxamine, and placebo: interaction with digoxin and effects on sleep and alertness. J. Clin. Pharmacol. 1989; 29: 91–95
   PubMed Web of Science ®Google Scholar
• Owen A., Pirmohamed M., Tettey J. N., Morgan P., Chadwick D., Park B. K. Carbamazepine is not a substrate for P-glycoprotein. Br. J. Clin. Pharmacol. 2001; 51: 345–349
   PubMed Web of Science ®Google Scholar
• Pavek P., Fendrich Z., Staud F., Malakova J., Brozmanova H., Laznicek M., Semecky V., Grundmann M., Palicka V. Influence of P-glycoprotein on the transplacental passage of cyclosporine. J. Pharm. Sci. 2001; 90: 1583–1592
   PubMed Web of Science ®Google Scholar
• Pavek P., Staud F., Fendrich Z., Sklenarova H., Libra A., Novotna M., Kopecky M., Nobilis M., Semecky V. Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123. J. Pharmacol. Exp. Ther. 2003; 305: 1239–1250
   PubMed Web of Science ®Google Scholar
• Pienimaki P., Hartikainen A. L., Arvela P., Partanen T., Herva R., Pelkonen O., Vahakangas K. Carbamazepine and its metabolites in human perfused placenta and in maternal and cord blood. Epilepsia 1995; 36: 241–248
   PubMed Web of Science ®Google Scholar
• Perlis R. H., Mischoulon D., Smoller J. W., Wan Y. J., Lamon-Fava S., Lin K. M., Rosenbaum J. F., Fava M. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol. Psych. 2003; 54: 879–883
   PubMed Web of Science ®Google Scholar
• Potschka H., Baltes S., Loscher W. Inhibition of multidrug transporters by verapamil or probenecid does not alter blood–brain barrier penetration of levetiracetam in rats. Epilepsy Res. 2004; 58: 85–91
   PubMed Web of Science ®Google Scholar
• Potschka H., Fedrowitz M., Loscher W. P-Glycoprotein-mediated efflux of phenobarbital, lamotrigine, and felbamate at the blood–brain barrier: evidence from microdialysis experiments in rats. Neurosci. Lett. 2002; 327: 173–176
   PubMed Web of Science ®Google Scholar
• Potschka H., Fedrowitz M., Loscher W. Multidrug resistance protein MRP2 contributes to blood–brain barrier function and restricts antiepileptic drug activity. J. Pharmacol. Exp. Ther. 2003a; 306: 124–131
   PubMed Web of Science ®Google Scholar
• Potschka H., Fedrowitz M., Loscher W. Brain access and anticonvulsant efficacy of carbamazepine, lamotrigine, and felbamate in ABCC2/MRP2-deficient TR- rats. Epilepsia 2003b; 44: 1479–1486
   PubMed Web of Science ®Google Scholar
• Potschka H., Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood–brain barrier of rats. Epilepsia 2001a; 42: 1231–1240
   PubMed Web of Science ®Google Scholar
• Potschka H., Loscher W. In vivo evidence for P-glycoprotein-mediated transport of phenytoin at the blood–brain barrier of rats. Epilepsia. 2001b; 42: 1231–1240
   PubMed Web of Science ®Google Scholar
• Prasad P. D., Hoffmans B. J., Moe A. J., Smith C. H., Leibach F. H., Ganapathy V. Functional expression of the plasma membrane serotonin transporter but not the vesicular monoamine transporter in human placental trophoblasts and choriocarcinoma cells. Placenta. 1996; 17: 201–207
   PubMed Web of Science ®Google Scholar
• Ramamoorthy S., Prasad P. D., Kulanthaivel P., Leibach F. H., Blakely R. D., Ganapathy V. Expression of a cocaine-sensitive norepinephrine transporter in the human placental syncytiotrophoblast. Biochemistry 1993; 32: 1346–1353
   PubMed Web of Science ®Google Scholar
• Rapeport W. G., Coates P. E., Dewland P. M., Forster P. L. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. J. Clin. Psych. 1996; 57(Suppl 1)16–19
   Google Scholar
• Rochat B., Baumann P., Audus K. L. Transport mechanisms for the antidepressant citalopram in brain microvessel endothelium. Brain Res. 1999; 831(1–2)229–236
   PubMed Web of Science ®Google Scholar
• Saito S., Iida A., Sekine A., Miura Y., Ogawa C., Kawauchi S., Higuchi S., Nakamura Y. Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J. Hum. Genet. 2002; 47: 147–171
   PubMed Web of Science ®Google Scholar
• Sakaeda T., Nakamura T., Horinouchi M., Kakumoto M., Ohmoto N., Sakai T., Morita Y., Tamura T., Aoyama N., Hirai M., Kasuga M., Okumura K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm. Res. 2001; 18: 1400–1404
   PubMed Web of Science ®Google Scholar
• Sato K., Sugawara J., Sato T., Mizutamari H., Suzuki T., Ito A., Mikkaichi T., Onogawa T., Tanemoto M., Unno M., Abe T., Okamura K. Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta 2003; 24: 144–148
   PubMed Web of Science ®Google Scholar
• Schenker S., Yang Y., Mattiuz E., Tatum D., Lee M. Olanzapine transfer by human placenta. Clin. Exp. Pharmacol. Physiol. 1999; 26: 691–697
   PubMed Web of Science ®Google Scholar
• Schinkel A. H., Wagenaar E., Mol C. A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996; 97: 2517–2524
   PubMed Web of Science ®Google Scholar
• Schinkel A. H., Jonker J. W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 2003; 55: 3–29
   PubMed Web of Science ®Google Scholar
• Schinkel A. H., Wagenaar E., Mol C. A., van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996; 97: 2517–2524
   PubMed Web of Science ®Google Scholar
• Seelig A., Blatter X. L., Wohnsland F. Substrate recognition by P-glycoprotein and the multidrug resistance-associated protein MRP1: a comparison. Int. J. Clin. Pharmacol. Ther. 2000; 38: 111–121
   PubMed Web of Science ®Google Scholar
• Sills G. J., Kwan P., Butler E., de Lange E. C., van den Berg D. J., Brodie M. J. P-glycoprotein-mediated efflux of antiepileptic drugs: Preliminary studies in mdr1a knockout mice. Epilepsy Behav. 2002; 3: 427–432
   PubMed Web of Science ®Google Scholar
• Silverman J. A. P-Glycoprotein. Metabolic Drug Interactions, René Levy. Lippincott-Raven Press. 2000; 135–144
   Google Scholar
• Smit J. W., Huisman M. T., van Tellingen O., Wiltshire H. R., Schinkel A. H. Absence or pharmacological blocking of placental P-glyroprotein profoundly increases fetal drug exposure. J Clin. Invest. 1999; 104: 1441–1447
   PubMed Web of Science ®Google Scholar
• Sparreboom A., Gelderblom H., Marsh S., Ahluwalia R., Obach R., Principe P., Twelves C., Verweij J., McLeod H. L. Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin. Pharmacol. Ther. 2004; 76: 38–44
   PubMed Web of Science ®Google Scholar
• Staud F., Fendrich Z., Jindrova O., Laznicek M. Phenytoin transfer across the in situ perfused rat term placenta. Pharmazie. 1997; 52: 871–874
   PubMed Web of Science ®Google Scholar
• Stevens J. C. New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology. Drug Discov. Today 2006; 11: 440–445
   PubMed Web of Science ®Google Scholar
• Stormer E., von Moltke L. L., Perloff M. D., Greenblatt D. J. P-glycoprotein interactions of nefazodone and trazodone in cell culture. J. Clin. Pharmacol. 2001; 41: 708–714
   PubMed Web of Science ®Google Scholar
• St-Pierre M. V., Hagenbuch B., Ugele B., Meier P. J., Stallmach T. Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J. Clin. Endocrinol. Metab. 2002; 87: 1856–1863
   PubMed Web of Science ®Google Scholar
• St-Pierre M. V., Ugele B., Gambling L., Shiverick K. T. Mechanisms of drug transfer across the human placenta-a workshop report. Placenta 2002; 23(Suppl A)S159–164
   PubMedGoogle Scholar
• Sugawara I., Kataoka I., Morishita Y., Hamada H., Tsuruo T., Itoyama S., Mori S. Tissue distribution of P-glycoprotein encoded by a multidrug-resistant gene as revealed by a monoclonal antibody, MRK 16. Cancer Res. 1988; 48: 1926–1929
   PubMed Web of Science ®Google Scholar
• Sun H., Dai H., Shaik N., Elmquist W. F. Drug efflux transporters in the CNS. Adv. Drug Deliv. Rev. 2003; 55: 83–105
   PubMed Web of Science ®Google Scholar
• Syme M. R., Paxton J. W., Keelan J. A. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet. 2004; 43: 487–514
   PubMed Web of Science ®Google Scholar
• Takano M., Hasegawa R., Fukuda T., Yumoto R., Nagai J., Murakami T. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur. J. Pharmacol. 1998; 358: 289–294
   PubMed Web of Science ®Google Scholar
• Tanabe M., Ieiri I., Nagata N., Inoue K., Ito S., Kanamori Y., Takahashi M., Kurata Y., Kigawa J., Higuchi S., Terakawa N., Otsubo K. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. 2001; 297: 1137–1143
   PubMed Web of Science ®Google Scholar
• Tolle-Sander S., Rautio J., Wring S., Polli J. W., Polli J. E. Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. Pharm. Res. 2003; 20: 757–764
   PubMed Web of Science ®Google Scholar
• Trixler M., Tenyi T. Antipsychotic use in pregnancy: What are the best treatment options?. Drug Saf. 1997; 16: 403–410
   PubMed Web of Science ®Google Scholar
• Trixler M., Gati A., Fekete S., Tenyi T. Use of antipsychotics in the management of schizophrenia during pregnancy. Drugs 2005; 65: 1193–1206
   PubMed Web of Science ®Google Scholar
• Ugele B., St-Pierre M. V., Pihusch M., Bahn A., Hantschmann P. Characterization and identification of steroid sulfate transporters of human placenta. Am. J. Physiol. Endocrinol. Metab. 2003; 284: E390–398
   PubMed Web of Science ®Google Scholar
• Uhr M., Steckler T., Yassouridis A., Holsboer F. Penetration of amitriptyline, but not of fluoxetine, into brain is enhanced in mice with blood-brain barrier deficiency due to mdr1a P-glycoprotein gene disruption. Neuropsychopharmacology. 2000; 22: 380–387
   PubMed Web of Science ®Google Scholar
• Uhr M., Grauer M. T. abcb1ab P-glycoprotein is involved in the uptake of citalopram and trimipramine into the brain of mice. J. Psychiatr. Res. 2003; 37: 179–185
   PubMed Web of Science ®Google Scholar
• Uhr M., Grauer M. T., Holsboer F. Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry 2003; 54: 840–846
   PubMed Web of Science ®Google Scholar
• Uhr M., Holsboer F., Muller M. B. Penetration of endogenous steroid hormones corticosterone, cortisol, aldosterone and progesterone into the brain is enhanced in mice deficient for both mdr1a and mdr1b P-glycoproteins. J. Neuroendocrinol. 2002; 14: 753–759
   PubMed Web of Science ®Google Scholar
• Unadkat J.D., Dahlin A., Vijay S. Placental drug transporters. Curr. Drug Metab. 2004; 5: 125–131
   PubMed Web of Science ®Google Scholar
• van Kalken C., Giaccone G., van der Valk P., Kuiper C. M., Hadisaputro M. M., Bosma S. A., Scheper R. J., Meijer C. J., Pinedo H. M. Multidrug resistance gene (P-glycoprotein) expression in the human fetus. Am. J. Pathol. 1992; 141: 1063–1072
   PubMed Web of Science ®Google Scholar
• Varga A., Nugel H., Baehr R., Marx U., Hever A., Nacsa J., Ocsovszky I., Molnar J. Reversal of multidrug resistance by amitriptyline in vitro. Anticancer Res. 1996; 16: 209–211
   PubMed Web of Science ®Google Scholar
• Verstuyft C., Robert A., Morin S., Loriot M.A., Flahault A., Beaune P., Funck-Brentano C., Jaillon P., Becquemont L. Genetic and environmental risk factors for oral anticoagulant overdose. Eur. J. Clin. Pharmacol. 2003; 58: 739–745
   PubMed Web of Science ®Google Scholar
• von Ahsen N., Richter M., Grupp C., Ringe B., Oellerich M., Armstrong V. W. No influence of the MDR-1 C3435T polymorphism or a CYP3A4 promoter polymorphism (CYP3A4-V allele) on dose-adjusted cyclosporin A trough concentrations or rejection incidence in stable renal transplant recipients. Clin. Chem. 2001; 47: 1048–1052
   PubMed Web of Science ®Google Scholar
• von Moltke L. L., Greenblatt D. J., Court M. H., Duan S. X., Harmatz J. S., Shader R. I. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J. Clin. Psychopharmacol. 1995; 15: 125–131
   PubMed Web of Science ®Google Scholar
• von Moltke L. L., Greenblatt D. J., Schmider J., Wright C. E., Harmatz J. S., Shader R. I. In vitro approaches to predicting drug interactions in vivo. Biochem. Pharmacol. 1998; 55: 113–122
   PubMed Web of Science ®Google Scholar
• von Moltke L. L., Weemhoff J. L., Perloff M. D., Hesse L. M., Harmatz J. S., Roth-Schechter B. F., Greenblatt D. J. Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm. Drug Dispos. 2002; 23: 361–367
   PubMed Web of Science ®Google Scholar
• Wang J. S., DeVane C. L., Gibson B. B., Donovan J. L., Markowitz J. S., Zhu H. J. Population pharmacokinetic analysis of drug-drug interactions among risperidone, bupropion, and sertraline in CF1 mice. Psychopharmacology (Berl). 2006; 183: 490–499
   PubMed Web of Science ®Google Scholar
• Wang J. S., Ruan Y., Taylor R. M., Donovan J. L., Markowitz J. S., DeVane C. L. The brain entry of risperidone and 9-hydroxyrisperidone are greatly limited by P-glycoprotein. Int J Neuropsychopharmacology 2004b; 7: 415–419
   PubMed Web of Science ®Google Scholar
• Wang J. S., Taylor R., Ruan Y., Donovan L. J., Markowitz S. J., DeVane C. L. (Olanzapine penetration inot brain is greater in transgenic mdr1a p-glycoprotein deficient mice than FVB1 (wild type) aminals. Neuropsychopharmacology 2004; 29: 551–557
   PubMed Web of Science ®Google Scholar
• Watson J. P., Elliott S. A., Rugg A. J., et al. Psychiatric disorder in pregnancy and the first postnatal year. Br. J. Psych. 1984; 144: 453–462
   PubMed Web of Science ®Google Scholar
• Weiss J., Kerpen C. J., Lindenmaier H., Dormann S. M., Haefeli W. E. Interaction of antiepileptic drugs with human P-glycoprotein in vitro. J. Pharmacol. Exp. Ther. 2003; 307: 262–267
   PubMed Web of Science ®Google Scholar
• Weissman M. M., Olfson M. Depression in women: Implications for health care research. Science 1995; 269: 799–801
   PubMed Web of Science ®Google Scholar
• Yaffe S. J. Drugs in Pregnancy and Lactation. Willams and Wilkins, Baltimore, MD 1998
   Google Scholar
• Yates C. R., Zhang W., Song P., Li S., Gaber A. O., Kotb M., Honaker M. R., Alloway R. R., Yu D. K. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 1999; 39: 1203–1211
   PubMed Web of Science ®Google Scholar
• Yavarone M. S., Shuey D. L., Sadler T. W., Lauder J. M. Serotonin uptake in the ectoplacental cone and placenta of the mouse. Placenta 1993; 14: 149–161
   PubMed Web of Science ®Google Scholar
• Young A. M., Allen C. E., Audus K. L. Efflux transporters of the human placenta. Adv. Drug Deliv. Rev. 2003; 55: 125–132
   PubMed Web of Science ®Google Scholar
• Zamber C. P., Lamba J. K., Yasuda K., Farnum J., Thummel K., Schuetz J. D., Schuetz E. G. Natural allelic variants of breast cancer resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics 2003; 13: 19–28
   PubMedGoogle Scholar
• Zheng H., Webber S., Zeevi A., Schuetz E., Zhang J., Bowman P., Boyle G., Law Y., Miller S., Lamba J., Burckart G. J. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant 2003; 3: 477–483
   PubMed Web of Science ®Google Scholar
• zu Schwabedissen H. E. M., Jedlitschky G., Gratz M., Haenisch S., Linnemann K., Fasch C., Cascorbi I., Kroemer H. K. Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab. Disp. 2005; 33: 896–904
   PubMed Web of Science ®Google Scholar